VM 106

Drug Profile

VM 106

Alternative Names: NADPH oxidase subunit gene therapy - ViroMed; VM106

Latest Information Update: 13 Oct 2010

Price : $50

At a glance

  • Originator ViroMed Co Ltd
  • Class Gene therapies
  • Mechanism of Action NADPH oxidase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Chronic granulomatous disease

Most Recent Events

  • 13 Oct 2010 Discontinued - Phase-I/II for Chronic granulomatous disease in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top